Kolexia
Frelaut Maxime Oncologie médicale
Frelaut Maxime
Oncologie médicale
Gustave-Roussy
Villejuif, France
80 Activités
64 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinome pulmonaire non à petites cellules Carcinome pulmonaire à petites cellules Tumeurs du poumon Lymphomes Tumeurs du rein COVID-19 Lymphome malin non hodgkinien Tumeurs du col de l'utérus Lymphome B

Collaborateurs

Voir plus
Besse Benjamin
Besse Benjamin
Gustave-Roussy, Villejuif, France
Borcoman Edith
Borcoman Edith
Clcc Institut Curie, Paris, France
Loirat Delphine
Loirat Delphine
Clcc Institut Curie, Paris, France
Le Tourneau Christophe
Le Tourneau Christophe
Clcc Institut Curie, Paris, France

Industries

Voir plus
Sandoz
2 collaboration(s)
Dernière en 2022
MSD
1 collaboration(s)
Dernière en 2023
Eisai
1 collaboration(s)
Dernière en 2020
Janssen
1 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
SHIVA02 - Evaluation of the Efficacy of Targeted Therapy Based on Tumor Molecular Profiling in Patients With Advanced Cancer Using Each Patient as Its Own Control
Essai Clinique (Institut Curie)   15 février 2024
Antibody drug conjugates in older patients: State of the art.
Critical reviews in oncology/hematology   24 novembre 2023
Cancer mortality and competing causes of death in older adults with cancer: A prospective, multicentre cohort study (ELCAPA-19).
Cancer medicine   08 novembre 2023
Bridging the gap: addressing disparities of access to oncology clinical trials in the geriatric population.
ESMO open   20 octobre 2023
2300P Clonal hematopoiesis of indeterminate potential (CHIP) in patients with advanced NSCLC treated with immune checkpoint blockers (ICB) as monotherapy: Analysis of the PREMIS study
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
1416P Recurrence of infusion-related reaction (IRRs) associated to avimantamab
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
80P Tumor microenvironment (TME) defines prognosis of EGFR-mutant non-small cell lung cancer (NSCLC)
Molecular Analysis for Precision Oncology Congress 2023 4-6 October 2023   01 octobre 2023
1334P Activity of first line immunotherapy or chemo-immunotherapy in advanced NSCLC with SMARCA4 deficiency
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
External Validity of Two Scores for Predicting the Risk of Chemotherapy Toxicity Among Older Patients With Solid Tumors: Results From the ELCAPA Prospective Cohort.
The oncologist   08 juin 2023
Predictors of three-month mortality and severe chemotherapy-related adverse events in patients aged 70 years and older with metastatic non-small-cell lung cancer: A secondary analysis of ESOGIA-GFPC-GECP 08-02 study.
Journal of geriatric oncology   19 mai 2023